§ Claim under review · Mixed
"Saffron is outperforming SSRIs in clinical trials. 1 in 5 Americans is prescribed an antidepressant every year... A 2025 meta-analysis - 12 randomized controlled trials, 728 patients - compared saffron directly against SSRIs including Prozac and Zoloft. The finding: Saffron matches the efficacy of Prozac and Zoloft... Saffron: 23% fewer adverse events than SSRIs in the meta-analysis. No withdrawal. No PSSD equivalent... The effective dose: 30mg of standardized Affron® extract (the extract used in the trials)."
Verdict
Partially accurate but misleading
Confidence
MediumSummary
The meta-analysis behind this post is real, but the post misstates it in several ways. Shafiee and colleagues, published in Nutrition Reviews in March 2025, pooled nine randomized trials, all conducted in Iran, and found no statistically significant difference between saffron and SSRIs for depression or anxiety symptoms, along with fewer reported side effects in the saffron groups. That is a null result, so saying saffron is "outperforming" SSRIs is not what the study found, and the post contradicts itself by also saying saffron only "matches" them. The figures of 12 trials, 728 patients, and 23% fewer adverse events do not come from the journal, they appear in a blog summary. The paper actually reported a 6 percentage point absolute difference in adverse events, and rated its own safety evidence as low certainty and its efficacy evidence as moderate, with small samples and short follow-up. The claims that saffron has no withdrawal and no persistent sexual dysfunction reflect the fact that these were never studied in short trials, not proof that they do not happen, and the named branded extract was tested against placebo rather than against SSRIs. The post's one solid caveat is worth keeping: this research concerns mild to moderate depression, and no one should stop an antidepressant without their doctor.
The readings
key figures from the evidencerisk difference in adverse events, saffron vs SSRIs
standardized mean difference in depression symptoms, saffron vs SSRIs
Why this verdict
Evidence
The cited meta-analysis is real. Shafiee et al. published "Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials" in Nutrition Reviews, Volume 83, Issue 3, March 2025, pages e751 to e761, searching PubMed, Embase, Scopus, Web of Science and Cochrane from inception to April 2023 for randomized controlled trials comparing saffron with SSRIs in adults with depression or anxiety.
Its findings, in the authors' own numbers: meta-analysis of 8 studies assessing depression outcomes revealed a nonsignificant difference between saffron and SSRIs in reducing depressive symptoms (SMD = 0.10; 95% CI: -0.09 to 0.29), and four studies reporting anxiety outcomes showed a nonsignificant difference (SMD = 0.04; 95% CI: -0.22 to 0.29) . On safety, participants receiving saffron had fewer adverse events than the SSRI group, expressed as a risk difference of -0.06 (95% CI: -0.09 to -0.04; I² = 0%) . The authors' conclusion is that saffron could be a potential SSRI alternative with fewer adverse events, and that further research with larger sample sizes and in diverse populations is warranted.
Critically, the study count and setting do not match the viral post. The indexed record states the review analyzed data from nine randomized controlled trials conducted in Iran, and that evidence quality was rated moderate for efficacy outcomes and low for safety outcomes, with limitations including small sample sizes and short follow-up durations.
The "12 trials, 728 patients, 23%" figures appear to originate in a blog post, not the paper. That blog states the analysis covered 12 randomized controlled trials involving 728 participants and that saffron demonstrated "a 23% lower risk of adverse effects" compared with SSRIs. Repeated searches for a saffron versus SSRI meta-analysis with 728 participants returned only the Shafiee paper, whose abstract and indexing describe nine trials.
METHODOLOGY AND CONTEXT
Design: Systematic review and random-effects meta-analysis of head-to-head RCTs. Randomized controlled trials comparing saffron with SSRIs in adults with depression or anxiety were included, with standardized mean differences for continuous outcomes and risk ratios for binary outcomes.
Number of trials: Nine RCTs total, with 8 contributing depression data and 4 contributing anxiety data. Not 12.
Setting: All included trials were conducted in Iran. Total pooled participant count could not be retrieved (full text is paywalled), so the "728 patients" figure is neither confirmed nor specifically refuted.
Comparators: Head-to-head saffron trials against SSRIs do exist, including fluoxetine comparisons and at least one sertraline comparison. Ahmadpanah et al. compared saffron with sertraline in 50 older outpatients with major depressive disorder, published in Psychiatry Research in 2019. So the reference to Prozac and Zoloft as comparators is plausible, though individual trials are very small.
Certainty of evidence: Moderate for efficacy, low for safety.
Product and dose: Affron is a specific commercial standardized extract studied mainly against placebo, not against SSRIs. In the 2025 Journal of Nutrition trial, 202 adults aged 18 to 70 with depressive symptoms received 28 mg saffron daily or placebo over 12 weeks.
In the earlier youth trial, Affron was also given as a standardized extract in a placebo-controlled design.
US antidepressant use: CDC data show that during 2015 to 2018, 13.2% of adults aged 18 and over used antidepressant medications in the past 30 days, with higher use among women (17.7%) than men (8.4%), and use highest among women aged 60 and over (24.3%).
PSSD regulatory status: In response to a petition and adverse event data in 2018, the European Medicines Agency recommended changes to SSRI and SNRI product labels to include information about persistent sexual dysfunction after stopping the medication , and labels have since been updated in Ireland, New Zealand, Canada, Hong Kong, Australia and Malaysia . On the US side, a clinical review notes that in the US the FDA recognizes this risk on the label of fluoxetine (Prozac) .
Findings
✓ What's accurate 6
- **The meta-analysis exists and is correctly dated.** It was published in Nutrition Reviews, volume 83, issue 3, March 2025.
- **Saffron and SSRIs did not differ significantly on symptom reduction** in the pooled analysis, for both depression and anxiety. Both pooled SMDs had confidence intervals crossing zero.
- **The saffron groups had fewer adverse events.** Risk difference -0.06 (95% CI: -0.09 to -0.04).
- **SSRI and fluoxetine comparators were used in real head-to-head trials**, including at least one sertraline comparison in older adults.
- **The post's own caveats are consistent with the evidence.** The literature base is in mild to moderate depression, and the advice not to stop SSRIs without medical supervision is appropriate.
- **Persistent sexual dysfunction after stopping SSRIs has regulatory recognition**, on the fluoxetine label in the US and more formally through the EMA process in Europe. ---
≈ What's misleading 10
- **"Outperforming SSRIs" (exaggeration, and direct contradiction of the source).** The paper found no statistically significant difference. A null difference is not outperformance. The post's own body text ("matches the efficacy") contradicts its own headline.
- **"Matches the efficacy" overstates a null result (temporal and statistical overreach).** Small, short trials that fail to detect a difference do not establish equivalence. These were not formally designed as non-inferiority trials, and the confidence interval for depression (-0.09 to 0.29) still permits a modest advantage for SSRIs.
- **"12 randomized controlled trials, 728 patients" does not match the source (fabricated or garbled specifics).** The record for the paper describes nine trials, with 8 and 4 contributing to the depression and anxiety analyses respectively. The 12 and 728 figures trace to a blog summary, not the journal.
- **"23% fewer adverse events" misrepresents the reported statistic (metric substitution).** The published abstract reports an absolute risk difference of 6 percentage points, not a 23% relative reduction. The 23% figure appears in the secondary blog. Even if a relative risk of about 0.77 appears in the paywalled full text, the safety evidence was graded low certainty, which the post omits.
- **Omitted qualifier: all nine trials were conducted in Iran**, were small, and had short follow-up, and certainty was moderate for efficacy and low for safety. None of this appears in the post.
- **"Saffron works on five: serotonin, dopamine, brain inflammation, cortisol, and cellular repair" (species extrapolation and mechanism-as-outcome).** Multi-pathway activity for saffron constituents comes largely from preclinical and mechanistic work, not from human outcome trials. Listing mechanisms is not evidence of superior clinical effect, and the trials in this very meta-analysis showed no efficacy advantage.
- **"That's why SSRIs often fail to treat anhedonia and low motivation" (unsupported causal inference).** The meta-analysis did not measure anhedonia or motivation as separate endpoints. Residual anhedonia on SSRIs is a genuine clinical topic, but nothing in the cited evidence links it to saffron's mechanisms or shows saffron treats it better.
- **"No withdrawal. No PSSD equivalent" (absence of evidence presented as evidence of absence).** Saffron trials in this literature are typically 6 to 12 weeks, were not designed to detect discontinuation syndromes, and did not systematically assess persistent sexual dysfunction. "Not studied" is not the same as "does not occur."
- **"30mg of standardized Affron® extract (the extract used in the trials)" (product misattribution and marketing framing).** Affron has been studied mainly against placebo at 28 mg per day, not against SSRIs. The SSRI head-to-head trials used other saffron preparations. Naming a single branded extract as "the extract used in the trials," followed by a lead-generation call to action, converts a null-difference research finding into product promotion.
- **"1 in 5 Americans is prescribed an antidepressant every year" (inflated statistic).** CDC 30-day-use data give 13.2% of adults, closer to 1 in 8. The 1 in 5 figure resembles subgroup rates such as women aged 60 and over at 24.3%, which is subgroup generalization. ---
? What's uncertain 5
- **Total participant count in the meta-analysis.** The full text is paywalled and the abstract does not state it, so "728" could not be confirmed or specifically refuted. The trial count, however, is confirmed as nine, not twelve.
- **Whether the paper's full text reports a relative risk of roughly 0.77 for adverse events.** The abstract states risk ratios were calculated, but only the risk difference is published in the abstract. This is why the 23% figure is classed as unverified rather than false.
- **Which specific nine trials were included**, and therefore whether sertraline comparisons were among them. This could not be confirmed at abstract level.
- **Long-term efficacy and safety of saffron**, including discontinuation effects, sexual function outcomes, dose standardization across products, and effects beyond 8 to 12 weeks. This remains unstudied in the head-to-head literature.
- **Generalizability outside Iran.** The authors themselves called for research in diverse populations, which implies this is unresolved. ---
Sources
8 of 8 linked to records**Shafiee A, Jafarabady K, Seighali N, et al. "Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials." Nutrition Reviews 2025;83(3):e751-e761**
**EBSCO structured research record for the same paper** (reports study count and GRADE ratings)
**CDC / NCHS Data Brief No. 377, "Antidepressant Use Among Adults: United States, 2015-2018"**
**Lopresti AL et al., Affron trial in adults with low mood, Journal of Nutrition 2025 (28 mg/day vs placebo)**
**Ahmadpanah M et al., "Crocus Sativus L. (saffron) versus sertraline... older people with MDD," Psychiatry Research 2019;282:112613**
**RxISK and PSSD Network regulator summaries; Carlat Report review of PSSD**
**scienceable.net, "Saffron vs SSRIs: 2025 Meta-Analysis Reveals Natural Spice Matches Antidepressants" (April/May 2025)**
**Widyarto WG et al., "Toward Holistic Psychiatry: Saffron, SSRIs..." Nutrition Reviews 2025 (letter responding to Shafiee et al.)**